Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other financing activities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Other financing activities for 15 consecutive years, with -$8.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities fell 2050.0% to -$8.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.3 million, a 2866.67% decrease, with the full-year FY2025 number at -$200000.0, up 50.0% from a year prior.
  • Other financing activities was -$8.6 million for Q4 2025 at Myriad Genetics, down from -$400000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.2 million in Q1 2021 to a low of -$8.6 million in Q4 2025.
  • A 4-year average of -$1.8 million and a median of $150000.0 in 2022 define the central range for Other financing activities.
  • Biggest YoY gain for Other financing activities was 2050.0% in 2025; the steepest drop was 2050.0% in 2025.
  • Myriad Genetics' Other financing activities stood at $1.2 million in 2021, then crashed by 41.67% to $700000.0 in 2022, then crashed by 157.14% to -$400000.0 in 2024, then crashed by 2050.0% to -$8.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Other financing activities are -$8.6 million (Q4 2025), -$400000.0 (Q4 2024), and $700000.0 (Q3 2022).